Hepatic decompensation associated with an interferon-free antiviral therapy in patients with HCV-cirrhosis


Cite item

Full Text

Abstract

Today, there is no complete clarity about the pathogenetic mechanisms of the hepatic decompensation in patients with HCV-cirrhosis during the course of direct-acting antiviral (DAAs) therapy. The current article describes several clinical observations of decompensation (with the development of liver failure and portal hypertension) in cirrhotic patients during the course of DAAs-therapy of hepatitis C. The authors present contemporary views and their own assumptions about the possible mechanisms of the hepatic decompensation associated with DAAs-therapy in patients with liver cirrhosis.

About the authors

S N Batskikh

A.S. Loginov Moscow Clinical Scientific and Practical Center, Moscow City Department of Health

Email: zdoc@mail.ru
к.м.н., с.н.с. отдела гепатологии ГБУЗ «МКНЦ им. А.С. Логинова» ДЗМ; н.с. ФБУН «Центральный НИИ эпидемиологии» Роспотребнадзора; ORCID iD 0000-0002-5917-203X Moscow, Russia

E V Vinnitskaya

A.S. Loginov Moscow Clinical Scientific and Practical Center, Moscow City Department of Health

д.м.н., зав. отделом гепатологии Moscow, Russia

Yu G Sandler

A.S. Loginov Moscow Clinical Scientific and Practical Center, Moscow City Department of Health

к.м.н., с.н.с. научно-исследовательского отдела гепатологии Moscow, Russia

T Yu Khaimenova

A.S. Loginov Moscow Clinical Scientific and Practical Center, Moscow City Department of Health

к.м.н., зав. отд-нием хронических заболеваний печени Moscow, Russia

References

  1. Jessica K. Dyson, John Hutchinson, Laura Harrison, Olorunda Rotimi, Dina Tiniakos, Graham R. Foster, Mark A. Aldersley, Stuart Mc Pherson. Liver toxicity associated with sofosbuvir, an NS5A inhibitor and ribavirin use. J Hepatology. 2016;64:234-8. https://doi.org/10.1016/ j.jhep.2015.07.041
  2. Jonathan G. Stine, Nicolas Intagliata, Neeral L. Shah, Curtis K. Argo, Stephen H. Caldwell, James H. Lewis, Patrick G. Northup. Hepatic decompensation likely attributable to simeprevir in patients with advanced cirrhosis. Digestive Disease and Sciences. 2015;60:1031-5. https://doi.org/10.1007/s10620-014-3422-x
  3. Martin-Walter Welker, Stefan Luhne, Christian M. Lange, Johannes Vermehren, Harald Farnik, Eva Herrmann, Tania Welzel, Stefan Zeuzem, Christoph Sarrazin. Lactic acidosis in patients with hepatitis C virus cirrhosis and combined ribavirin/ sofosbuvir treatment. J Hepatology. 2016;64:790-9. https://doi.org/10.1016/j.jhep.2015.11.034
  4. Fred Poordad, David R. Nelson, Jordan J. Feld, Michael W. Fried, Heiner Wedemeyer, Lois Larsen, Daniel E. Cohen, Eric Cohen, Niloufar Mobashery, Fernando Tatsch, Graham R. Foster. Safety of the 2D/3D direct - acting antiviral regimen in HCV-induced Child-Pugh A cirrhosis - A pooled analysis. J Hepatology. 2017;67:700-7. https://doi.org/10.1016/j.jhep.2017.06.011
  5. Bart J. Veldt, E. Jenny Heathcote, Heiner Wedemeyer, Juerg Reichen, W. Peter Hofmann, Stefan Zeuzem, Michael P. Manns, Bettina E. Hansen, Solko W. Schalm, Harry L.A. Janssen. Sustained virologic response and clinical outcomes in patients with chronic hepatitis C and advanced fibrosis. Ann Intern Med. 2007;147(10):677-84. https://doi.org/10.7326/0003-4819-147-10-200711200-00003
  6. Adriaan J. van der Meer, Bart J. Veldt, Jordan J. Feld, Heiner Wedemeyer, Jean-François Dufour, Frank Lammert, Andres Duarte-Rojo, E. Jenny Heathcote, Michael P. Manns, Lorenz Kuske, Stefan Zeuzem, W. Peter Hofmann, Robert J. de Knegt, Bettina E. Hansen, Harry L. A. Janssen. Association between sustained virological response and all - cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA. 2012;308(24):2584-93. https://doi.org/ 10.1001/jama.2012.144878
  7. Rebecca L. Morgan, Brittney Baack, Bryce D. Smith, Anthony Yartel, Marc Pitasi, Yngve Falck-Ytter. Eradication of hepatitis C virus infection and the development of hepatocellular carcinoma: a meta - analysis of observational studies. Ann Intern Med. 2013;158(5 Pt 1):329-37. https://doi.org/10.7326/0003-4819-158-5-201303050-00005
  8. Heiner Wedemeyer, Jens Reimer, Petra Sandow, Dietrich Hueppe, Thomas Lutz, Kurt Gruengreiff, Joerg Goelz, Stefan Christensen, Heike Pfeiffer-Vornkahl, UlrichAlshuth, Michael P. Mann. Long - term Outcome of Chronic Hepatitis C (CHC) Virus Infection in a Real-World Setting: The German LOTOS Study. Liver International. 2017;37:1468-75. https://doi.org/10.1111/liv.13399
  9. Jay H. Hoofnagle. Hepatic decompensation during direct - acting antiviral therapy of chronic hepatitis C. J Hepatology. 2016;646:763-5. https://doi.org/10.1016/j.jhep.2016.01.007
  10. Welker M.W, Luhne S, Lange C.M, Farnik H, Herrmann E, Welzel T, Zeuzem S, Christoph S. Lactic acidosis in patients with hepatitis C virus cirrhosis and combined ribavirin/ sofosbuvir treatment. J Hepatology. 2016;64:790-9. https://doi.org/10.1016/j.jhep.2015.11.034
  11. Scheiner B, Lindner G, Reiberger T, Schneeweiss B, Trauner M, Zauner C, Funk G.C. Acid - base disorders in liver disease. J Hepatology. 2017;67:1062-73. https://doi.org/10.1016/j.jhep.2017.06.023
  12. Vanwolleghem T, Meuleman P, Libbrecht L, Roskams T, De Vos R, Leroux-Roels G. Ultra-Rapid Cardiotoxicity of the Hepatitis C Virus Protease Inhibitor BILN 2061 in the Urokinase-Type Plasminogen Activator Mouse. Gastroenterology. 2007;133(4):1144-55. https://doi.org/ 10.1053/j.gastro.2007.07.007
  13. Sheridan C. Calamitous HCV trial casts shadow over nucleoside drugs. Nature Biotechnology. 2012;30:1015-6. https://doi.org/10.1038/ nbt1112-1015
  14. Arnold J.J, Sharma S.D, Feng J.Y, Ray A.S, Smidansky E.D, Kireeva M.L, Cho A, Perry J, Vela J.E, Park Y, Xu Y, Tian Y, Babusis D, Barauskus O, Peterson B.R, Gnatt A, Kashlev M, Zhong W, Cameron C.E. Sensitivity of Mitochondrial Transcription and Resistance of RNA Polymerase II Dependant Nuclear Transcription to Antiviral Ribonucleosides. PLoS Pathogens. 2012;8(11):e1003030. https://doi.org/10.1371/ journal.ppat.1003030
  15. Mc Kenzie R, Fried M.W, Sallie R, Conjeevaram H, Di Bisceglie A.M, Park Y, Savarese B, Kleiner D, Tsokos M, Luciano C, Pruett T, Stotka J.L, Straus S.E, Hoofnagle.JH. Hepatic failure and lactic acidosis due to fialuridine (FIAU), an investigational nucleoside analogue for chronic hepatitis B. N Engl J Med. 1995;333:1099-105. https://doi.org/10.1056/nejm199510263331702
  16. Tujios S, Fontana R.J. Mechanisms of drug - induced liver injury: from bedside to bench. Nature Reviews Gastroenterology & Hepatology. 2011 Apr;8(4):202-11. https://doi.org/10.1038/nrgastro.2011.22
  17. Xu D, Nishimura T, Nishimura S, Zhang H, Zheng M, Guo Y.Y, Masek M, Michie S.A, Glenn J, Peltz G. Fialuridine induces acute liver failure in chimeric TK-NOG mice:a model for detecting hepatic drug toxicity prior to human testing. PLoS Med. 2014;11:31001628. https://doi.org/10.1371/journal.pmed.1001628
  18. Coats S.J, Garnier-Amblard E.C, Amblard F, Ehteshami M, Amiralaei S, Zhang H, Zhou L, Boucle S.R.L, Lu X, Bondada L, Shelton J.R, Li H, Liu P, Li C, Cho J.H, Chavre S.N, Zhou S, Mathew J, Schinazi R.F. Chutes and ladders in hepatitis C nucleoside drug development. Antiviral Res. 2014;102:119-47. https://doi.org/10.1016/ j.antiviral.2013.11.008
  19. Renet S, Chaumais M.C, Antonini T, Zhao A, Thomas L, Savoure A, Samuel D, Duclos-Vallée J.C, Algalarrondo V. Extreme bradycardia after first doses of sofosbuvir and daclatasvir in patients receiving amiodarone: 2 cases including a rechallenge. Gastroenterology. 2015;149(6):1378-80. https://doi.org/10.1053/j.gastro.2015.07.051
  20. EASL Recommendations on Treatment of Hepatitis C 2016. J Hepatology. 2017;66:153-94. https://doi.org/10.1016/j.jhep.2016.09.001
  21. AASLD/IDSA HCV Guidance Panel Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus. Hepatology. 2015;4(62)3:932-54. https://doi.org/10.1002/hep.27950
  22. Dufour J.H, Dziejman M, Liu M.T, Leung J.H, Lane T.E, Luster A.D. IFN-gamma - inducible protein 10 (IP-10; CXCL10)-deficient mice reveal a role for IP-10 in eff ector T cell generation and trafficking. J Immunol. 2002;168:3195-204. https://doi.org/10.4049/ jimmunol.168.7.3195
  23. Edward J Gane, Stuart K Roberts, Catherine A.M Stedman, Peter W Angus, Brett Ritchie, Rob Elston, David Ipe, Peter N Morcos, Linda Baher, Isabel Najera, Tom Chu, Uri Lopatin, M Michelle Berrey, William Bradford, Mark Laughlin, Nancy S Shulman, Patrick F Smith. Oral combination therapy with a nucleoside polymerase inhibitor (RG7128) and danoprevir for chronic hepatitis C genotype 1 infection (INFORM-1): a randomised, double - blind, placebo - controlled, dose - escalation trial. Lancet. 2010;376:1467-75. https://doi.org/10.1016/ s0140-6736(10)61384-0
  24. Meike H. van der Ree, Femke Stelma, Sophie B. Willemse, Anthony Brown, Leo Swadling, Marc van der Valk, Marjan J. Sinnige, Ad C. van Nuenen, J. Marleen L. de Vree, Paul Klenerman, Eleanor Barnes, Neeltje A. Kootstra, Hendrik W. Reesink. Immune responses in DAA treated chronic hepatitis C patients with and without prior RG-101 dosing. Antiviral Research. 2017;146:139-45. https://doi.org/10.1016 j.antiviral.2017.08.016
  25. Eric G. Meissner, David Wu, Anu Osinusi, Dimitra Bon, Kimmo Virtaneva, Dan Sturdevant, Steve Porcella, Honghui Wang, Eva Herrmann, John Mc Hutchison, Anthony F. Suffredini, Michael Polis, Stephen Hewitt, Ludmila Prokunina-Olsson, Henry Masur, Anthony S. Fauci, Shyamasundaran Kottilil. Endogenous intrahepatic IFNs and association with IFN-free HCV treatment outcome. J Clinical. 2014;124:3352-63. https://doi.org/10.1172/jci75938
  26. Jens M. Werner, Akinbami Adenugba, Ulrike Protzer. Immune Reconstitution After HCV Clearance With Direct Antiviral Agents: Potential Consequences for Patients With HCC? Transplantation. 2017;101(5):904-9. https://doi.org/10.1097/tp.0000000000001606
  27. Oldford S.A, Arseneault K, Barrett L. Early Immune Changes during HCV DAA Therapy in an Incarcerated Population. J Hepatology. 2016;64:525-26. https://doi.org/10.1016/s0168-8278(16)00926-0

Copyright (c) 2018 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 
 


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies